What is the role of andexanet alfa in the reversal of anticoagulant effects?

被引：3

作者：

Sewell, Jenna Hill ^{[1
]}

Williams, LaKeisha ^{[2
]}

McKnight, Ellen ^{[3
]}

Nguyen, Anthony ^{[4
]}

Sarac, Miroslav ^{[5
]}

机构：

[1] Gulf Coast Vet Healthcare Syst, Biloxi, MS 39531 USA

[2] Xavier Univ Louisiana, Coll Pharm, New Orleans, LA USA

[3] Walgreens Pharm, Memphis, TN USA

[4] Ochsner Med Ctr, New Orleans, LA USA

[5] Univ Business Acad Novi Sad, Fac Pharm, Novi Sad, Serbia

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2021年 / 34卷 / 01期

关键词：

andexanet alfa; anticoagulant; reversal; apixaban; rivaroxaban; antidote;

D O I：

10.1097/01.JAA.0000723956.47623.90

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although using direct oral anticoagulants increases patient risk for hemorrhagic events, FDA-approved options for reversing anticoagulant effects are limited. This article discusses one of the more recent FDA-approved antidotes, andexanet alfa, and provides guidelines for its safe and effective use.

引用

页码：8 / 9

页数：2

共 50 条

[1] Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies
Escolar, G.
Diaz-Ricart, M.
Arellano-Rodrigo, E.
[J]. DRUGS OF TODAY, 2017, 53 (05) : 271 - 282
[2] Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
Hu, Tiffany Y.
Vaidya, Vaibhav R.
Asirvatham, Samuel J.
[J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 35 - 44
[3] Andexanet alfa for the reversal of factor Xa inhibitors
Favresse, J.
Hardy, M.
van Dievoet, M. A.
Sennesael, A. L.
Douxfils, J.
Samama, C. M.
Vornicu, O.
Dincq, A. S.
Lessire, S.
Mullier, F.
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (05) : 387 - 397
[4] Andexanet Alfa for Factor Xa Inhibitor Reversal
Wang, Josh J.
Gosselin, Sophie
Villeneuve, Eric
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (25): : 2498 - 2498
[5] Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal
Koo, Soo Jin
Hussain, Yunus
Booth, Deborah Y.
Desai, Payal
Oh, Elly S.
Rios, Jose
Audley, Kristen
[J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2024, 64 (02) : 395 - 401
[6] Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage
Takasaki, Kaoru
Hehir, David
Raffini, Leslie
Samelson-Jones, Benjamin J.
Shih, Evelyn
Dain, Aleksandra Sarah
[J]. PEDIATRIC BLOOD & CANCER, 2022, 69 (06)
[7] Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Siegal, Deborah M.
Curnutte, John T.
Connolly, Stuart J.
Lu, Genmin
Conley, Pamela B.
Wiens, Brian L.
Mathur, Vandana S.
Castillo, Janice
Bronson, Michele D.
Leeds, Janet M.
Mar, Florie A.
Gold, Alex
Crowther, Mark A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25): : 2413 - 2424
[8] FEIBA AND ANDEXANET ALFA FOR THE REVERSAL OF APIXABAN AND RIVAROXABAN IN UNCONTROLLED HEMORRHAGE
Ice, Calvin
Gurka, Matthew
Parker, Jessica
Hunt, Aleah
[J]. CRITICAL CARE MEDICINE, 2022, 50 (01) : 449 - 449
[9] Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent
Powell, Jason
Taylor, James
Garland, Scott G.
[J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (09) : 940 - 946
[10] Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation
Ghadimi, Kamrouz
Dombrowski, Keith E.
Levy, Jerrold H.
Welsby, Ian J.
[J]. EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (02) : 115 - 122

← 1 2 3 4 5 →